# BRIUMVI® (ublituximab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ublituximab

> The FDA approved BRIUMVI® (ublituximab), sponsored by TG THERAPEUTICS, INC. (TGTX), on June 30, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is BRIUMVI® (ublituximab) FDA approved?

Yes. The FDA approved BRIUMVI® (ublituximab), sponsored by TG THERAPEUTICS, INC. (TGTX), on June 30, 2025. SEC Form 10-Q: "At June 30, 2025, our inventory was solely related to BRIUMVI, which was approved by the FDA in December 2022, at which time we began to capitalize costs to manufacture BRIUMVI." [Calendar and source filings](https://sec-api.dev/pdufa/ublituximab)

Source: SEC Form 10-Q, accession 0001437749-25-025745, https://www.sec.gov/Archives/edgar/data/1001316/000143774925025745/tgtx20250630_10q.htm (retrieved 2026-11-12). Last confirmed 2025-08-08. Cite: https://sec-api.dev/pdufa/ublituximab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | BRIUMVI® (ublituximab) |
| Codes | TG-1101 |
| Sponsor | TG THERAPEUTICS, INC. (TGTX) https://sec-api.dev/companies/tgtx/catalysts |
| Indications | [relapsing forms of multiple sclerosis](https://sec-api.dev/indications/relapsing-forms-of-multiple-sclerosis), achr-antibody-positive mg, rms and in january 2025, [Relapsing Multiple Sclerosis](https://sec-api.dev/indications/relapsing-multiple-sclerosis), [Schizophrenia](https://sec-api.dev/indications/schizophrenia), [Multiple Sclerosis](https://sec-api.dev/indications/multiple-sclerosis), [Myasthenia Gravis](https://sec-api.dev/indications/myasthenia-gravis) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### December 28, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2025-03-03, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001437749-25-015804): "On December 28, 2022, we announced the FDA approval of BRIUMVI for the treatment of RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, primarily based on results from the ULTIMATE I & II Phase 3 trials." https://www.sec.gov/Archives/edgar/data/1001316/000143774925015804/tgtx20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-033363): "In December 2022, we announced the FDA approval of BRIUMVI for the treatment of RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, primarily based on results from the ULTIMATE I & II Phase 3 trials." https://www.sec.gov/Archives/edgar/data/1001316/000143774925033363/tgtx20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025745): "In December 2022, we announced the FDA approval of BRIUMVI for the treatment of RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, primarily based on results from the ULTIMATE I & II Phase 3 trials." https://www.sec.gov/Archives/edgar/data/1001316/000143774925025745/tgtx20250630_10q.htm
- SEC Form 10-K (accession 0001437749-25-005908): "At December 31,2024, all our inventory was solely related to BRIUMVI, which was approved by the FDA on December 28, 2022, at which time we began to capitalize costs to manufacture BRIUMVI." https://www.sec.gov/Archives/edgar/data/1001316/000143774925005908/tgtx20241231_10k.htm

### 2025: trial start

- Status: scheduled. Date confidence: year. Stage: 1. Indication: RMS and in January 2025.
- First seen 2025-03-03, last confirmed 2025-03-03.
- SEC Form 10-K (accession 0001437749-25-005908): "In August 2024, we announced the initiation of a Phase 1 clinical trial evaluating subcutaneous ublituximab in patients with RMS and in January 2025, at the Annual J.P. Morgan Healthcare Conference we announced our plans to commence a pivotal program in 2025 evaluating a subcutaneous ublituximab with an expected dosing frequency of at least every other month." https://www.sec.gov/Archives/edgar/data/1001316/000143774925005908/tgtx20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-005908): "Additionally, in 2025, we expect to commence a pivotal program evaluating a self-administered subcutaneous BRIUMVI product with an improved dosing frequency, commence pivotal trials aimed at further optimizing intravenous BRUIMVI for patients with RMS, evaluate BRIUMVI in other autoimmune diseases outside of MS and commence a Phase 1 clinical trial evaluating azer-cel for the treatment of primary progressive MS." https://www.sec.gov/Archives/edgar/data/1001316/000143774925005908/tgtx20241231_10k.htm

### March 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-09, last confirmed 2025-05-09.
- SEC Form 10-Q (accession 0001437749-25-015804): "At March 31, 2025, all our inventory was solely related to BRIUMVI, which was approved by the FDA on December 28, 2022, at which time we began to capitalize costs to manufacture BRIUMVI." https://www.sec.gov/Archives/edgar/data/1001316/000143774925015804/tgtx20250331_10q.htm

### May 5, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-05-05, last confirmed 2025-05-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-014402): "TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/ex_811168.htm

### June 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-08, last confirmed 2025-08-08.
- SEC Form 10-Q (accession 0001437749-25-025745): "At June 30, 2025, our inventory was solely related to BRIUMVI, which was approved by the FDA in December 2022, at which time we began to capitalize costs to manufacture BRIUMVI." https://www.sec.gov/Archives/edgar/data/1001316/000143774925025745/tgtx20250630_10q.htm

### August 4, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-08-04, last confirmed 2025-08-04.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-024480): "TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/ex_846995.htm

### November 3, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-11-03, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032658): "TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/ex_860184.htm

### February 26, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-005733): "TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/ex_887198.htm

### May 6, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-06, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015013): "TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm

### May 27, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: relapsing forms of multiple sclerosis.
- First seen 2026-05-27, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-018586): "NEW YORK, May 27, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS)." https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/ex_968837.htm
- SEC Form 10-Q (accession 0001437749-26-025955): "In May 2026, we announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS)." https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025955): "In May 2026, we announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI in adults with relapsing forms of multiple sclerosis (RMS)." https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm

### Jun 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1. Indication: AChR-antibody-positive MG.
- First seen 2026-08-05, last confirmed 2026-08-05.
- SEC Form 10-Q (accession 0001437749-26-025955): "In June 2026, we announced positive topline data from an ongoing Phase 1 clinical trial evaluating subcutaneous BRIUMVI in patients with AChR-antibody-positive MG." https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm

### August 3, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-08-03, last confirmed 2026-08-03.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-025304): "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-05-06, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07211633
- Press release filed with the SEC (EX-99) (accession 0001437749-26-019262): "Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027" https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/ex_970980.htm
- SEC Form 10-Q (accession 0001437749-26-015246): "In April 2026, we announced the Phase 3 trial evaluating subcutaneous BRIUMVI completed enrollment and topline data is expected around year-end 2026 or first quarter 2027." https://www.sec.gov/Archives/edgar/data/1001316/000143774926015246/tgtx20260331_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-071870): "Top-line Phase 3 data are expected by year-end 2026 or early 2027." https://www.sec.gov/Archives/edgar/data/1001316/000162828026071870/q3-26earningsprxexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-025304): "Top-line Phase 3 data is expected year-end 2026 or early 2027" https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-019262): "The Phase 3 trial has completed enrollment, and topline results are expected in late 2026 or early 2027." https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/ex_970980.htm
- SEC Form 10-Q (accession 0001628280-26-072257): "Topline data from the Phase 3 trial is expected around year-end 2026 or first quarter 2027." https://www.sec.gov/Archives/edgar/data/1001316/000162828026072257/tgtx-20260930.htm
- SEC Form 10-Q (accession 0001437749-26-025955): "Topline data from the Phase 3 trial is expected around year-end 2026 or first quarter 2027." https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07211633

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05877963

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05877963

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07503873

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07503873

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07673744

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07673744

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07680946

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07680946

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07220252

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07220252 (Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07220252

## Same indication

- [ALTO-101](https://sec-api.dev/pdufa/alto-101) (ANRO)
- [Anavex3-71 oral capsules](https://sec-api.dev/pdufa/anavex3-71-oral) (AVXL)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Cariprazine flexible dose](https://sec-api.dev/pdufa/cariprazine-flexible-dose) (ABBV)
- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine) (ABBV)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [GXV813](https://sec-api.dev/pdufa/gxv813) (NVS)
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone) (VNDA)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [KYV-101](https://sec-api.dev/pdufa/kyv-101) (KYTX)
- [Lb-102 (50 mg tablet)](https://sec-api.dev/pdufa/lb-102) (LBRX)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [ML-007C-MA](https://sec-api.dev/pdufa/ml-007c-ma) (MPLT)
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid) (MPLT)
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195) (MRNA)
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568) (NBIX)
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570) (NBIX)
- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab) (JNJ)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Olz/sam](https://sec-api.dev/pdufa/olz-sam) (ALKS)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) (NVS)
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide) (SNY)
- [Tolebrutinib](https://sec-api.dev/pdufa/tolebrutinib) (SNY)
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium) (BMY)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ublituximab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BRIUMVI® (ublituximab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ublituximab

```bibtex
@misc{secapidev_pdufa_ublituximab_20261116,
  title        = {BRIUMVI® (ublituximab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ublituximab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ublituximab_20261116","title":"BRIUMVI® (ublituximab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ublituximab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
